KIF25: A Potential Drug Target and Biomarker (G3834)

Target Name: KIF25

NCBI ID: G3834

KIF25

KIF25: A Potential Drug Target and Biomarker

KIF25, also known as Kinesin-like 3 (KL-3), is a protein that plays a critical role in the intracellular transport of various molecules, including small molecules, ions, and proteins. It is a member of the Kinesin family, which is known for their ability to transport molecules along the cytoskeleton in a venerable manner. KIF25 is unique in that it is a protein that is both cytoplasmic and membrane-bound, which allows it to interact with both the cytoskeleton and the cell membrane.

KIF25 has been shown to play a key role in the regulation of various cellular processes, including cell division, cell migration, and the transport of intracellular vesicles. It is also involved in the regulation of ion channels, which are critical for the proper functioning of the cell membrane. KIF25 has been shown to interact with a variety of different molecules, including microtubules, actinins, and various signaling proteins.

One of the most promising aspects of KIF25 is its potential as a drug target. Its unique cytoplasmic and membrane-bound status makes it an attractive target for small molecule inhibitors, as well as antibodies that can specifically target it. Additionally, KIF25's role in intracellular transport makes it a potential target for drugs that are designed to modulate cellular transport processes.

KIF25 has also been shown to play a key role in the regulation of cellular signaling pathways. It is involved in the regulation of the Chasms, which is a critical pathway for the regulation of cell growth and differentiation. Additionally, KIF25 is involved in the regulation of the RhoA GTPase, which is a key regulator of cell signaling.

KIF25 is also a good candidate as a biomarker for certain diseases, such as cancer. Its involvement in the regulation of cellular processes makes it a potential target for drugs that are designed to inhibit its activity. Additionally, its cytoplasmic and membrane-bound status makes it an attractive target for antibodies that can specifically target it.

In conclusion, KIF25 is a protein that has the potential to be a drug target or biomarker. Its unique cytoplasmic and membrane-bound status makes it an attractive target for small molecule inhibitors, antibodies, and drugs that are designed to modulate cellular transport processes. Additionally, its involvement in the regulation of cellular signaling pathways makes it a potential target for drugs that are designed to inhibit its activity. Further research is needed to fully understand the role of KIF25 in cellular processes and its potential as a drug target or biomarker.

Protein Name: Kinesin Family Member 25

Functions: Minus-end microtubule-dependent motor protein (By similarity). Acts as a negative regulator of centrosome separation required to prevent premature centrosome separation during interphase (PubMed:28263957). Required to maintain a centered nucleus to ensure that the spindle is stably oriented at the onset of mitosis (PubMed:28263957). May also act as a negative regulator of amino acid starvation-induced autophagy (PubMed:22354037)

The "KIF25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets